Matthew R. Ruth Net Worth

The estimated Net Worth of Matthew R. Ruth is at least $629 Tisíc dollars as of 20 July 2022. Mr Ruth owns over 1,084 units of Opiant Pharmaceuticals Inc stock worth over $617,765 and over the last 3 years he sold OPNT stock worth over $11,512.

Mr Ruth OPNT stock SEC Form 4 insiders trading

Mr has made over 2 trades of the Opiant Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 1,084 units of OPNT stock worth $11,512 on 20 July 2022.

The largest trade he's ever made was buying 2,000 units of Opiant Pharmaceuticals Inc stock on 31 August 2021 worth over $34,680. On average, Mr trades about 514 units every 54 days since 2021. As of 20 July 2022 he still owns at least 29,916 units of Opiant Pharmaceuticals Inc stock.

You can see the complete history of Mr Ruth stock trades at the bottom of the page.

Mr. Matthew R. Ruth biography

Matthew R. Ruth is the Chief Commercial Officer at Opiant Pharmaceuticals Inc.

How old is Mr Ruth?

Mr Ruth is 51, he's been the Chief Commercial Officer of Opiant Pharmaceuticals Inc since . There are 6 older and 3 younger executives at Opiant Pharmaceuticals Inc. The oldest executive at Opiant Pharmaceuticals Inc is Michael Sinclair, 77, who is the Executive Chairman of the Board.

What's Mr Ruth's mailing address?

Matthew's mailing address filed with the SEC is C/O OPIANT PHARMACEUTICALS, INC., 233 WILSHIRE BLVD, SUITE 400, SANTA MONICA, CA, 90401.

Insiders trading at Opiant Pharmaceuticals Inc

Over the last 21 years, insiders at Opiant Pharmaceuticals Inc have traded over $16,027,532 worth of Opiant Pharmaceuticals Inc stock and bought 199,545 units worth $2,080,156 . The most active insiders traders include Craig A Collard, Marc A Cohen a Alain J Cohen. On average, Opiant Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of $159,046. The most recent stock trade was executed by Roger Crystal on 27 January 2023, trading 1,358 units of OPNT stock currently worth $27,513.

What does Opiant Pharmaceuticals Inc do?

Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.

Complete history of Mr Ruth stock trades at Opiant Pharmaceuticals Inc

Opiant Pharmaceuticals Inc executives and stock owners

Opiant Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Roger Crystal,
  President, Chief Executive Officer, Director
• Michael Sinclair,
  Executive Chairman of the Board
• Dr. Roger Crystal,
  Pres, CEO & Director
• Dr. Phil Skolnick D.Sc. (hon), Ph.D.,
  Chief Scientific Officer
• David D. O'Toole,
  Chief Financial Officer
• Michael Porter,
  IR Contact Officer
• Richard Daly,
  Independent Director
• Craig Collard,
  Independent Director
• Thomas Thomas,
  Director
• Gabrielle Silver,
  Director
• Ann MacDougall,
  Director
• Aziz Mottiwala,
  Chief Commercial Officer
• Rahsaan Thompson,
  General Counsel
• Phil Skolnick,
  Chief Scientific Officer
• Arvind Agrawal,
  Executive Vice President - Medical Affairs
• David O'Toole,
  Chief Financial Officer
• Matthew R. Ruth,
  Chief Commercial Officer
• Dr. Mark Heath Ellison Ph.D.,
  Chief Devel. Officer
• Brian Gorman,
  EVP Corp. Devel. & Gen. Counsel
• Ben Atkins,
  VP of Communications & Investor Relations
• Matthew R. Ruth,
  Chief Commercial Officer
• Ronald W Kaiser,
  Director
• Melvin Iii Wesley,
  Chief Financial Officer
• William F Stasior,
  Director
• Steven G Finn,
  Director
• Joseph W Kuhn,
  VP & Chief Financial Officer
• Alain J Cohen,
  President & Chief Tech Officer
• Marc A Cohen,
  Chairman, CEO, Treas, & Sec
• Brian Gorman,
  
• Mark Jason Heath Ellison,
  Chief Development Officer
• Masuoka K. Lorianne,
  Director